MA-BOSTONGENE
14.12.2021 15:17:21 CET | Business Wire | Press release
BostonGene Corporation and NEC Corporation (NEC; TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer BostonGene Tumor PortraitTM Tests in key international markets, including Japan as the first market outside of the U.S.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005500/en/
BostonGene’s innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system and the effectiveness of all available approved and experimental treatments. BostonGene Tumor Portrait™ Tests, based on integrated genomic and transcriptomic analysis, propel precision medicine into daily clinical practice and support physicians in actualizing personalized therapy for cancer patients.
Moreover, in NEC’s ongoing personalized neoantigen clinical trial that utilizes its AI-driven neoantigen prediction technology, NEC and BostonGene are collaborating to provide molecular characterization of patient tumors. Going forward, the two companies will jointly develop the market for BostonGene Tumor Portrait™ Tests globally. In Japan, the companies aim to utilize NEC's healthcare and life science network in order to provide Tumor Portrait™ Tests to hospitals throughout the country.
In 2020, 378,385 people died of cancer in Japan, according to a Ministry of Health, Labor, and Welfare report. This accounts for 27.6% of all deaths that year and equates to one in four people dying of cancer. Leveraging NEC’s longstanding relationships with cancer centers, pharma and biotech companies, the organizations will work closely together to demonstrate the critical role of next generation multi-platform analytics combined with cutting-edge software to improve the diagnosis and treatment for cancer patients. Earlier this year, NEC announced an initiative to create healthcare and life science business that utilizes AI and other digital technologies as part of the "creation of future growth businesses" set forth in the 2025 Mid-term Management Plan.
“NEC has been committed to contributing to healthcare for more than half a century, which includes state-of-the-art hospital information systems in Japan. Cancer is now the country’s most common cause of death, and NEC has been working with the National Cancer Center Japan since 2016. Today, NEC remains as dedicated as ever to applying our rich experience in AI and analytics for improving patients’ outcomes,” said Takayuki Morita, President and CEO at NEC Corporation. “BostonGene’s offering of deep molecular and immune profiling, coupled with its computational power and analytics, have already improved the quality of care for cancer patients in both academic and community settings in the United States. Supporting BostonGene’s international expansion enables us to continue to rapidly drive innovation that improves the standard of care in Japan and abroad.”
“NEC has a long history of offering industry leading products and solutions in the field of healthcare both in Japan and globally,” said Andrew Feinberg, President and CEO at BostonGene. “Partnering with NEC will allow BostonGene to expedite our international expansion which aims to improve the standard of care for cancer patients around the world.”
This agreement expands upon existing collaborations between BostonGene and NEC.
About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com .
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security, efficiency and equality of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nippon Electric Glass’s IR Transmitting Glass “FI-02” Adopted for Heimann Sensor Lens Unit, Enabling a 120° × 68° Field of View16.9.2026 03:00:00 CEST | Press release
Nippon Electric Glass Co., Ltd. (NEG) (TOKYO: 5214), a global leader in specialty glass headquartered in Otsu, Japan, announced that its IR Transmitting Glass (chalcogenide glass) “FI-02” has been adopted for Heimann Sensor GmbH’s wide-angle lens unit for thermal cameras. The lens unit achieves a 120° × 68° field of view, surpassing the previous product’s maximum of 92° × 59°. The adoption marks a significant milestone for FI-02 and showcases how advanced specialty glass can meet the demanding optical and manufacturing requirements of the expanding infrared sensing market. Thermal cameras detect infrared radiation emitted by people or objects and convert it into thermal images. Infrared sensors can detect the locations of people and temperature distributions. They are expected to be used for people detection and monitoring, where privacy considerations are important, and for air-conditioning control, while their use is expanding in healthcare, equipment monitoring, and security. Advanc
Workiva Advances Regulatory Work with AI Innovation15.9.2026 17:00:00 CEST | Press release
Agent Studio anchors AI capabilities unveiled at Amplify 2026 Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, unveiled dozens of new product and platform innovations at Amplify 2026, the company’s annual conference attended by thousands of finance, accounting, sustainability, risk, and compliance leaders. Workiva Debuts Agent Studio Workiva introduced Agent Studio, a landmark platform capability that empowers users to quickly build, customize, and deploy AI agents in Workiva's trusted platform. By combining AI reasoning with Workiva's native platform capabilities, enterprise knowledge, and governed workflows, Agent Studio enables users to automate sophisticated manual business processes without writing any code. Organizations can enrich agents with company-specific knowledge and context, tailor them to their own processes, and schedule automations to execute recurring work. “With Agent Studio, we're putting the power to build in the
Study: Heatwaves Increase Cough Urge, Which Salt Aerosols Reduce15.9.2026 15:15:00 CEST | Press release
New Study Indicates Non-Pharmacological Aerosol May Provide Therapeutic Relief for Respiratory Conditions Provoked by the Atmospheric Aridity Inherent to Heatwaves SC Therapeutics, with University North Carolina, Imperial College London, and Boston University, announced publication on Tuesday in Nature Scientific Reports of results from a multi-institutional study indicating that the aridity inherent in heatwaves increases cough hypersensitivity in human airways by collapsing mucus onto cilia in a manner common to chronic respiratory diseases, such as cystic fibrosis, and asthma. The researchers find that alkaline aerosols of magnesium salts reverse mucosal collapse for several hours, and reduce cough hypersensitivity as reflected in placebo-adjusted suppression of daily cough bout rate (59%, p=0.03) and persistence of suppression post treatment for 1 to 3 weeks in a randomized, double-blind, placebo-controlled study of 10 refractory chronic cough patients. “Paris recorded 5,764 excess
ADM’s Fourth Annual Regenerative Agriculture Report Highlights Growing Resilience Across the Food System15.9.2026 15:00:00 CEST | Press release
2025 programs engaged more than 56,000 farmers across 4.6 million acres in 11 countries ADM (NYSE: ADM), a global leader in innovative solutions from nature, today released its fourth annual regenerative agriculture report, showing how its programs are supporting farmers, strengthening agricultural supply chains and delivering measurable environmental outcomes around the world. “Resilience starts on the farm. By improving and protecting soil health, farmers can be better equipped to adapt to changing conditions and maintain productive operations,” said Greg Morris, SVP and President, Ag Services and Oilseeds, ADM. “That resilience can extend across the value chain, helping strengthen the food system we all depend on.” In 2025, ADM’s regenerative agriculture programs engaged more than 56,000 farmers across approximately 4.6 million acres, 11 countries and 10 crops. Compared with regional benchmarks, the programs resulted in approximately 946,000 metric tons of CO₂e reductions. “ADM view
Diligent Unveils New Agentic Capabilities in Diligent One to Power the Future of Governance, Risk and Compliance15.9.2026 15:00:00 CEST | Press release
New capabilities help organizations move from fragmented information to confident action while keeping people in control Diligent, the AI leader in governance, risk and compliance (GRC) solutions, today announced a major enhancement to Diligent One, its native AI platform, at Gartner’s Enterprise Risk, Audit and Compliance Conference (ERAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915941016/en/ “For many organizations, GRC work is slowed by fragmented systems, manual coordination and time-consuming reporting processes,” said Brian Stafford, President and CEO of Diligent. “Our latest agentic capabilities help teams cut through that complexity by connecting context, surfacing what matters and driving faster execution — while keeping governance and professional judgement at the center." An orchestration agent that coordinates work and approvals The orchestration agent in Diligent One gives GRC professionals a natural-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom